Interestingly, high mRNA expression of CISD1 can impact the prognosis of hepatocellular carcinoma patients who were treated with sorafenib indicating that the CISD1 antagonist may enhance the anti-HCC effect of sorafenib. Here, CISD1 is linked to hepatocellular carcinoma.